Scroll down for Important Safety Information.
MeltDose is a registered trademark of LifeCycle Pharma A/S Corporation, Denmark.
For more information on MeltDose Technology, Click here.
Manufactured by Catalent Pharma Solutions for Sciele Pharma, Inc., a Shionogi company.
Fenoglide is a fenofibrate prescribed to treat adults with hyperlipidemia (high cholesterol in the blood), mixed dyslipidemia (a combination of high LDL cholesterol, high triglycerides, and low HDL cholesterol), or hypertriglyceridemia (high triglyceride levels in the blood) in combination with eating a healthy diet low in saturated fat and cholesterol.
Fenoglide tablets offer lower dosage so that you can consume less drug while treating your cholesterol levels.
Fenoglide administration is contraindicated in patients with: known hypersensitivity to fenofibrate or any of the formulation components; severely impaired renal function including dialysis patients; gallbladder disease; active liver disease, including primary biliary cirrhosis and unexplained persistent liver function abnormality; and nursing mothers.
Fenofibrate can increase serum transaminases. Regular periodic liver tests should be performed, and therapy discontinued if enzyme levels persist >3 times the normal limit.
Fenofibrate may lead to cholelithiasis. If cholelithiasis is confirmed, Fenoglide should be discontinued. Patients should take Fenoglide at least 1 hour before or 4-6 hours after a bile acid binding resin.
Fenoglide may increase the effects of coumarin-type anticoagulants. Dosage adjustment based on frequent prothrombin time/International Normalized Ratio determinations is advisable.
The combined use of Fenoglide and HMG-CoA Reductase Inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk. This combination has been associated with rhabdomyolysis, markedly elevated creatine kinase levels and myoglobinuria, leading to acute renal failure.
Treatment with fenofibrate increases risk of myopathy. Treatment with fenofibrate increases risk of rhabdomyolysis. Muscle pain, tenderness, or weakness warrants prompt medical evaluation. Discontinue Fenoglide if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed.
The effect of Fenoglide on coronary heart disease morbidity and mortality, and noncardiovascular mortality has not been established.
Due to the potential risk of deterioration for renal function, the combined use of fenofibrates with immunosuppressants, cyclosporine, and other potentially nephrotoxic agents should be carefully considered and the lowest effective dose of fenofibrate employed. Fenofibrate should be avoided in patients with severely impaired renal function including dialysis patients.
Other adverse events include: pancreatitis, hypersensitivity reactions, and mild to moderate hematologic changes. Adverse events most frequently observed in clinical trials: abnormal liver tests; respiratory disorder; abdominal pain; back pain; and headache.
Click here for Full Prescribing Information.
Ask your healthcare professional if Fenoglide is right for you or call (800) 849-9707 ext 1454.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
Images are for illustrative purposes only.
For more information about dosing and how Fenoglide compares to other cholesterol medications, contact us today.